|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Our results guide new therapeutic options for GD2.CAR-Ts in patients with neuroblastoma, and CAR-T development for a broad range of solid tumors.
|
30617136 |
2019 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.
|
30999624 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although CAR-T cell therapy did not have satisfactory responses in solid tumors, researchers were still holding an optimistic attitude towards its future efficacy with more modifications of its structure.
|
30886654 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Further evaluation showed that pSM3-CAR effectively caused tumor necrosis, providing new options for improved CAR-T therapy in solid tumors.
|
26961900 |
2016 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR T-cell Therapy for Solid Tumors?
|
30291124 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells have shown promising efficacy in treatment of hematological malignancies, but its applications in solid tumors need further exploration.
|
28366766 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clinical success of CAR-T cell monotherapy in solid tumors however, has been only modest.
|
30298067 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, the performance of CAR-T cell treatment in solid tumor is not as satisfactory as that in hematologic disease.
|
29769134 |
2018 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Here, we reviewed the solid tumor CAR-T clinical trials, emphasizing the studies with published results.
|
29433552 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The presence of sCAR in MPE puts forward the notion that in certain contexts (e.g., within the extracellular matrix of solid tumors) the concentrations of secreted (or shed) CAR may be high enough to effectively compete with Ad gene delivery.
|
12060636 |
2002 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Identifying targets for chimeric antigen receptor-modulated T lymphocyte (CAR-T) therapy against solid tumors is an urgent problem to solve.
|
29935762 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Researchers increased the effectiveness of CAR T-cell therapy in solid tumors by injecting the cells near the tumors.
|
25583818 |
2015 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Application of the CAR targeting strategy in solid tumors is challenged by the need for adequate target antigens.
|
30483473 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Innovative approaches such as haploidentical stem cell transplantation, new monoclonal antibodies and immunotherapies as well as Chimeric Antigen Receptor T-cell (CAR-T cell) therapies are on the way as promising treatment options especially for patients with refractory hematologic malignancies and even in solid tumors.
|
29556955 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Chimeric antigen receptor-modified (CAR-modified) T cells have shown promising therapeutic effects for hematological malignancies, yet limited and inconsistent efficacy against solid tumors.
|
29769444 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR design optimization for solid tumors is crucial due to the absence of truly restricted antigen expression and potential safety concerns with "on-target off-tumor" activity.
|
29061641 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR-T cell therapy has achieved gratifying breakthrough in hematological malignancies and promising outcome in solid tumor as showed in various clinical trials.
|
28356156 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid tumors is crucial for tumor clearance.
|
29505028 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Due to their high heterogeneity and complex tumor microenvironment, the treatment of solid tumors by CAR-T cell technology is limited.
|
31497363 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The obstacles that reduce the efficacy of CAR-T therapy in solid tumors include a lack of specific tumor antigens, limited trafficking and penetration of CAR-T cells to tumor sites, and an immunosuppressive tumor microenvironment.
|
29861325 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The anti-VEGFR2 CAR but not mock T cells mediated specific lysis of 293-KDR cells expressing human VEGFR2 and might be considered as a candidate for adoptive T-cell immunotherapy of solid tumors.
|
30724452 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This strategy may facilitate the application of immunotherapy to solid tumors by affording comparable efficacy with improved safety owing to switch-based control of the CAR-T response.
|
27145250 |
2016 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The tumor vasculature an attractive CAR T cell target in solid tumors.
|
31628559 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although CAR T cell therapy mediates robust responses in patients with hematological malignancies, this approach has been less effective for treating patients with solid tumors.
|
30842774 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this review, we discuss the structure of the CAR, current clinical advantages from finished and ongoing trials, adverse effects, challenges and controversies, new engineering methods of CAR, and clinical considerations that are associated with CAR T cell therapy both in hematological malignancies and solid tumors.
|
30108584 |
2018 |